1. Homepagina
  2. Aandelen
  3. BelgiŽ
  4. Euronext Bruxelles
  5. Argenx SE
  6. Nieuws
  7. Andere talen
    ARGX   NL0010832176

ARGENX SE

(ARGX)
  Rapport
Real Time Euronext Bruxelles  -  17:39 01-07-2022
362.70 EUR   +1.45%
28/06ARGENX SE : Stifel Nicolaus handhaaft koopadvies
MM
27/06BEURS VAN BRUSSEL : Bel20 sluit flink hoger onder leiding van Argenx
AM
27/06Argenx ontvangt positief CHMP-advies voor Efgartigimod voor de behandeling van volwassen patiënten met gegeneraliseerde Myasthenia Gravis in Europa
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Nieuws in andere talen op ARGENX SE
29/06US Futures Marginally Higher Ahead of Final Q1 GDP Reading
27/06ARGENX : Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patien..
27/06Argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patie..
24/06Argenx Gets Positive CHMP Opinion for Generalized Myasthenia Gravis Drug
24/06Argenx Gets EU Committee's Positive Opinion For Generalized Myasthenia Gravis Treatment
24/06argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patie..
24/06Argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patie..
17/06European ADRs Move Lower in Friday Trading
16/06TRANSCRIPT : Argenx SE Presents at Goldman Sachs 43rd Annual Global Healthcare Conference,..
07/06European ADRs Move Higher in Tuesday Trading
03/06European ADRs Move Lower in Friday Trading
01/06argenx to Present at Upcoming Investor Conferences
01/06Argenx to Present at Upcoming Investor Conferences
31/05Argenx's Generalized Myasthenia Gravis Therapy Gets Positive Scientific Opinion By UK W..
31/05argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized M..
31/05Argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized M..
19/05argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin B..
19/05argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin B..
19/05Argenx SE Announces Publication of Translational Data of Efgartigimod in Autoimmune Ski..
13/05ACTUALIZACIÓN DE LAS GRANDES EVOLUCI : final de la semana en verde
13/05European ADRs Move Higher in Friday Trading
13/05POINT SUR LES FORTES VARIATIONS DU J : fin de semaine dans le vert
13/05POINT SUR LES FORTES VARIATIONS DU J : Somfy remercie MSCI, UCB maudit la FDA
13/05Ça va piquer, mais on n'a pas le choix
13/05AVIS D'ANALYSTES DU JOUR : TotalEnergies, Roche, Ubisoft, ArgenX, SMA Solar, SoftwareOne, ..
11/05TRANSCRIPT : Argenx SE Presents at Bank of America 2022 Healthcare Conference, May-11-2022..
11/05Investitionen verhageln Evotec das Ergebnis - Aktie im Sinkflug
10/05argenx announces results of Annual General Meeting of Shareholders
10/05Argenx announces results of Annual General Meeting of Shareholders
10/05European ADRs Move Higher in Tuesday Trading
05/05SECTOR UPDATE : Health Care Stocks Tumbling in Late Trade
05/05SECTOR UPDATE : Health Care Stocks Dropping in Afternoon Trade
05/05Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART(R)..
05/05European ADRs Decline in Thursday Trading
05/05SECTOR UPDATE : Health Care Stocks Decline Premarket Thursday
05/05TRANSCRIPT : Argenx SE, Q1 2022 Earnings Call, May 05, 2022
05/05POINT SUR LES FORTES VARIATIONS DU J : mini-séisme pour CGG, Airbus à haute altitude
05/05Argenx Says Vyvgart Drug Improved Platelet Count in Patients With Bleeding Disorder
05/05Argenx Q1 Loss Widens
05/05Argenx's Bleeding Disorder Drug Improves Platelet Count in Late-Stage Study
05/05Argenx Forecasts $1 Billion Cash Utilization in FY22
05/05argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGARTģ (efgartigimod alf..
05/05argenx Reports First Quarter 2022 Financial Results and Provides Business Update
05/05Argenx Reports First Quarter 2022 Financial Results and Provides Business Update
05/05Argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGARTģ (efgartigimod alf..
05/05Argenx SE Announces Positive Phase 3 Data from ADVANCE Trial of VYVGARTģ (efgartigimod ..
05/05Argenx SE Reports Earnings Results for the First Quarter Ended March 31, 2022
04/05argenx to Present at BofA Securities 2022 Healthcare Conference
04/05Argenx to Present at BofA Securities 2022 Healthcare Conference
28/04ARGENX : argenx to Report First Quarter 2022 Financial Results and Business Update on May ..
28/04Argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 20..
22/04BB Biotech plombé au 1er trimestre par des marchés capricieux
05/04Argenx SE Says Long-Term Vyvgart Treatment Reduces Generalized Myasthenia Gravis Sympto..
05/04Argenx's Myasthenia Gravis Drug Shows Improved Disease Scores In Late-stage Extension T..
05/04Argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGA..
05/04Argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGA..
01/04argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American ..
01/04Argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American ..
30/03Argenx's Capital Raise Grows To $805 Million After Underwriters Exercise Option
29/03Argenx announces full exercise of underwriters' option to purchase additional ADSs
29/03Argenx announces Annual General Meeting of Shareholders on May 10, 2022
29/03Argenx Raises $700 Million Via Share Issue
28/03argenx announces closing of global offering
25/03ARGENX : announces launch of proposed global offering - Form 6-K
24/03Argenx Prices $700 Million Global Offering
24/03Argenx Prices $700 Million Global Offering
24/03Argenx raises $700 million in gross proceeds in a global offering
23/03Argenx Initiates $500 Million Global Share Offering
22/03Argenx Launches $500 Million Stock Offering; Shares Down 4% After Hours
22/03argenx announces launch of proposed global offering
22/03SECTOR UPDATE : Health Care Stocks Mixed on Tuesday
22/03Halozyme Therapeutics Says Argenx's Phase 3 Trial in Generalized Myasthenia Gravis Meet..
22/03ARGENX : Announces Positive Topline Phase 3 Data from ADAPT-SC Study Evaluating Subcutaneo..
22/03Argenx SE Announces Positive Topline Phase 3 Data from ADAPT-SC Study Evaluating Subcut..
22/03TRANSCRIPT : Argenx SE - Special Call
1  2  3  4  5  6  7  8  9  10Volgende